Polyclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) Mus musculus (Mouse) Polyclonal antibody

EAT; MCL1L; MCL1S; BCL2L3; TM; Myeloid Cell Leukemia Sequence 1, Bcl2 Related; Bcl-2-like protein 3; Bcl-2-related protein EAT/mcl1; mcl1/EAT

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Polyclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) Packages (Simulation)
  • Polyclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) Packages (Simulation)
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Specifity

The antibody is a rabbit polyclonal antibody raised against MCL1. It has been selected for its ability to recognize MCL1 in immunohistochemical staining and western blotting.

Usage

Western blotting: 0.5-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.

Storage

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Giveaways

Citations

  • Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid LeukemiaPubmed: 31718075
  • Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastomaPubmed: 32410663
  • BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 58133540760

Recommend products